GlassScriptPhysician profile
William R Baumann
NPI 1912926445
$1,203.01
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $590 · 2020: $597 · 2022: $15.41.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $285.47 | 2019-2020 | |
| Harmony Biosciences LLC | $161.24 | 2020 | |
| Jazz Pharmaceuticals INC. | $150.00 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.51 | 2019-2020 | |
| Mylan Specialty L.P. | $99.48 | 2019-2020 | |
| Glaxosmithkline, LLC. | $87.34 | 2019-2020 | |
| Genzyme Corporation | $77.97 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $48.48 | 2019-2020 | |
| Insmed, INC. | $40.99 | 2019 | |
| Shire North American Group INC | $35.35 | 2019 | |
| Electromed, INC. | $34.34 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $24.74 | 2019 | |
| Grifols USA, LLC | $22.81 | 2020 | |
| Abbvie INC. | $15.41 | 2022 | |
| Circassia INC. | $12.88 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Baumann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.